Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2013

01.02.2013 | short review

Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

verfasst von: Lucie Sramkova, MD, PhD, Jaroslav Sterba, Hana Hrstkova, Vladimir Mihal, Bohumir Blazek, Pavel Timr, Zdena Cerna, Daniela Prochazkova, Jiri Hak, Petr Sedlacek, Iveta Janotova, Elena Vodickova, Zuzana Zemanova, Marie Jarosova, Alexandra Oltova, Katerina Zdrahalova, Ondrej Hrusak, Ester Mejstrikova, Jiri Schwarz, Jan Zuna, Jan Trka, Jan Stary

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Treatment of childhood acute myeloid leukemia (AML) was unified in the year 1993 according to acute myeloid leukemia-Berlin–Frankfurt–Munster (AML-BFM) protocols in the Czech Republic. We evaluated data on clinical and therapeutic results in children with AML treated in three subsequent trials, comparing two periods, June 1993 to February 2004 (AML-BFM 93 and 98) vs. March 2004 to December 2009 (AML-BFM 2004 trial).

Patients and methods

Data of 182 eligible patients were analyzed, 125 in AML-BFM 93 and 98 trials, and 57 in AML-BFM 2004 trial enrolled prior to December 2009. Down syndrome patients were excluded from analysis.

Results

In studies AML-BFM 93 and 98, 79.2 % of 125 patients achieved complete remission (CR), 19 patients (15.2 %) suffered from early death, 7 (5.6 %) were nonresponders, 33 (33.3 %) relapsed, 12 (12.1 %) died in CR, and 2 patients (2.0 %) developed secondary malignancy. The estimated probability of event-free survival (pEFS) at 5 years was 41.6 %, the overall survival (OS) at 5 years was 46.4 %. In AML-BFM 2004 trial, 93 % of 57 patients attained CR, 3 patients (5.2 %) suffered from early death, 1 (1.8 %) was nonresponder, 16 (30.2 %) relapsed, 2 (3.8 %) died in CR, and 2 patients (3.5 %) developed secondary malignancy. The estimated pEFS at 5 years was 56.1 %, 5-years overall survival (5y-OS) was 73.7 %.

Conclusion

Gradual improvement of CR rate and OS together with decreasing incidence of toxic deaths in AML patients were achieved because of gain of experience with very intensive modern treatment centralized in a limited number of institutions.
Literatur
1.
Zurück zum Zitat Stary J, Gajdos P, Blazek B, et al. Unification of treatment of childhood acute myeloid leukemia in the Czech Republic according to AML BFM 93 study protocol. Cas Lek ces. 2004;143:257–63. (In Czech). Stary J, Gajdos P, Blazek B, et al. Unification of treatment of childhood acute myeloid leukemia in the Czech Republic according to AML BFM 93 study protocol. Cas Lek ces. 2004;143:257–63. (In Czech).
2.
Zurück zum Zitat Stary J, Vavra V, Gajdos P, et al. Second national study AML-BFM 98 improved remission rate and overall survival in children with acute myeloid leukemia in the Czech Republic. Trans Hemat dnes 2008;14:166–74. (In Czech). Stary J, Vavra V, Gajdos P, et al. Second national study AML-BFM 98 improved remission rate and overall survival in children with acute myeloid leukemia in the Czech Republic. Trans Hemat dnes 2008;14:166–74. (In Czech).
3.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMed Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–5.PubMed
4.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325–29.PubMedCrossRef Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325–29.PubMedCrossRef
5.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460–2.PubMed Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460–2.PubMed
6.
Zurück zum Zitat Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302–9.PubMedCrossRef Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20:2302–9.PubMedCrossRef
7.
Zurück zum Zitat Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96.PubMedCrossRef Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114:2489–96.PubMedCrossRef
8.
Zurück zum Zitat Casillas JN, Woods WG, Hunger SP, et al. Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol. 2003;25:594–600.PubMedCrossRef Casillas JN, Woods WG, Hunger SP, et al. Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children’s Cancer Group. J Pediatr Hematol Oncol. 2003;25:594–600.PubMedCrossRef
9.
Zurück zum Zitat Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104:630–9.PubMedCrossRef Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104:630–9.PubMedCrossRef
10.
Zurück zum Zitat Creutzig U, Zimmermann M, Bourquin JP, et al. Study AML-BFM 2004: results of a randomized induction with ether liposomal daunorubicin (L-DNR) or idarubicin. (Submitted for Publication) Creutzig U, Zimmermann M, Bourquin JP, et al. Study AML-BFM 2004: results of a randomized induction with ether liposomal daunorubicin (L-DNR) or idarubicin. (Submitted for Publication)
11.
Zurück zum Zitat Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705–13.PubMed Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol. 2001;19:2705–13.PubMed
12.
Zurück zum Zitat Neuhoff Ch, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28:2682–9.PubMedCrossRef Neuhoff Ch, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28:2682–9.PubMedCrossRef
13.
Zurück zum Zitat Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15:348–54.PubMedCrossRef Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15:348–54.PubMedCrossRef
14.
Zurück zum Zitat Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef
15.
Zurück zum Zitat Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multiinstitutional clinical trial AML-BFM 93. Leukemia. 2004;18:72–7.PubMedCrossRef Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multiinstitutional clinical trial AML-BFM 93. Leukemia. 2004;18:72–7.PubMedCrossRef
16.
Zurück zum Zitat Creutzig U, Zimmerman M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384–93.PubMedCrossRef Creutzig U, Zimmerman M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol. 2004;22:4384–93.PubMedCrossRef
17.
Zurück zum Zitat Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative antracycline doses. Report from the AML-BFM study group. Br J Haematol 2010;149:399–409.PubMedCrossRef Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative antracycline doses. Report from the AML-BFM study group. Br J Haematol 2010;149:399–409.PubMedCrossRef
18.
Zurück zum Zitat Zdrahalova K, Sedlacek P, Smisek P, et al. Study Relapsed AML 2001/01, 02 for children with relapsed acute myeloid leukemia or initially resistant disease improved their survival outcome. Trans Hemat dnes. 2011;17:113–21. (In Czech). Zdrahalova K, Sedlacek P, Smisek P, et al. Study Relapsed AML 2001/01, 02 for children with relapsed acute myeloid leukemia or initially resistant disease improved their survival outcome. Trans Hemat dnes. 2011;17:113–21. (In Czech).
Metadaten
Titel
Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic
verfasst von
Lucie Sramkova, MD, PhD
Jaroslav Sterba
Hana Hrstkova
Vladimir Mihal
Bohumir Blazek
Pavel Timr
Zdena Cerna
Daniela Prochazkova
Jiri Hak
Petr Sedlacek
Iveta Janotova
Elena Vodickova
Zuzana Zemanova
Marie Jarosova
Alexandra Oltova
Katerina Zdrahalova
Ondrej Hrusak
Ester Mejstrikova
Jiri Schwarz
Jan Zuna
Jan Trka
Jan Stary
Publikationsdatum
01.02.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0059-3

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe